LEUVEN, Belgium, April 13, 2012 /PRNewswire/ -- ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic

LEUVEN, Belgium, February 24, 2012 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines,

NAUGATUCK, Conn., July 8, 2011 /PRNewswire/ -- Effective July 1, 2011, Environmental Products Corporation (Envipco), a subsidiary of Envipco Holding N.V., a publicly listed company on the Brussels Euronext Exchange ("ENV"), entered into a distribution agreement with TOMRA/CBSI LLC in the State of Michigan.

LEUVEN, Belgium, June 7, 2011 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that Patrik De Haes, the Chief Executive Officer of ThromboGenics will present an overview of the Company's strategy and key development programs at the Jefferies 2011 Global Life Sciences Conference at the Grand Hyatt Hotel in New York City, U.S.

BRUSSELS, January 19, 2011 /PRNewswire-FirstCall/ -- From Monday January 24th, 2011, Rentabiliweb's share (BE0946620946 - BIL) will be joining NYSE Euronext Compartment B. Less than one year after its transfer to NYSE Euronext (February 15th, 2010), Rentabiliweb is confirming the success of its stock market development and the relevance of its strategic plan with this change of compartment. Compartment B groups together stocks with a market capitalization of between EUR150 million and EUR1 billion.